• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Senseonics up on Q4 earnings beat, upcoming U.S. launch of Eversense E3

March 2, 2022 By Sean Whooley

Eversense CGM Senseonics
The Eversense CGM [Image courtesy of Senseonics]
Senseonics (NYSE:SENS) shares are up today on Q4 earnings ahead of the consensus forecast, with the company planning to launch its next-gen, implantable, 6-month CGM in the U.S next month.

The Germantown, Maryland-based company posted revenues of $4 million for the three months ended Dec. 31, 2021, representing sales growth of 2.6% from the same period in 2020.

Adjusted to exclude one-time items, earnings per share were 1¢, 4¢ ahead of expectations on Wall Street, where analysts were looking for sales of $4 million.

“Following recent FDA approval, we are excited to make Eversense E3, an industry-leading 6-month sensor, available to patients and health care providers in the U.S. in early April. Our partner Ascensia is establishing a newly dedicated CGM commercial organization to drive both adoption and awareness of the Eversense E3,” Senseonics President and CEO Tim Goodnow said in a news release. “We are excited to continue advancing our long-term implantable sensor pipeline and IDE pivotal study approval for our next-generation one-year sensor this year.”

Senseonics said it expects to log global net revenues between $14 million and $18 million for the full 2022 fiscal year.

SENS shares were up more than 7% at $1.90 apiece by mid-day trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up slightly.

BTIG analysts Marie Thibault and Sam Eiber list Senseonics stock as a “neutral” buy, mentioning the upcoming Eversense E3 launch that will see adoption impacted by payor coverage. The analysts wrote that the timing and pace of payor transition to the 180-day CGM is “uncertain and expected to take several quarters.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Patient Monitoring, Wall Street Beat Tagged With: Senseonics

IN CASE YOU MISSED IT

  • Tandem Diabetes Care names successor as CEO Sheridan retires
  • MiniMed names new CMO ahead of planned retirement
  • Insulet earnings trounce Q3 estimates as it narrows guidance
  • Dexcom Q3 earnings top forecasts, as it looks ahead to type 2 coverage
  • Sensonics launches human feasibility study for transmitter-free Eversense CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS